ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Factor V Leiden, Heterozygous
Gene/Gene Panel: F5
Context: Adult
Date
Status
Release
Outcomes-Interventions
Notes
2024/03/24
Released
1.4.4
A
VTE (GroupA)
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Pharmacological prophylaxis (GroupA) 5CA
Assessment for VTE risk factors (GroupA) IN
System migration to fix the sem versioning
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
F5 ⇔ 0008560 THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2
Moderate Actionability
Limited Actionability
2024/03/24
Released (Under revision)
A
VTE (GroupA)
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Pharmacological prophylaxis (GroupA) 5CA
Assessment for VTE risk factors (GroupA) IN
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
F5 ⇔ 0008560 THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2
Moderate Actionability
Limited Actionability
2022/11/21
Released
A
VTE (GroupA)
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Pharmacological prophylaxis (GroupA) 5CA
Assessment for VTE risk factors (GroupA) IN
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
F5 ⇔ 0008560 THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2
Moderate Actionability
Limited Actionability
2022/03/30
Released (Under revision)
1.4.2
A
VTE (GroupA)
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Pharmacological prophylaxis (GroupA) 5CA
Assessment for VTE risk factors (GroupA) IN
Internal system migration associated with MONDO name addition.
2022/02/09
Released
1.4.2
A
VTE (GroupA)
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Pharmacological prophylaxis (GroupA) 5CA
Assessment for VTE risk factors (GroupA) IN
Internal system migration associated with MONDO name addition.
2022/02/09
Released (Under revision)
1.4.1
A
VTE (GroupA)
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Pharmacological prophylaxis (GroupA) 5CA
Assessment for VTE risk factors (GroupA) IN
2020/04/28
Released
1.4.1
A
VTE (GroupA)
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Pharmacological prophylaxis (GroupA) 5CA
Assessment for VTE risk factors (GroupA) IN
2020/04/28
Released (Under revision)
1.4.0
A
VTE (GroupA)
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Pharmacological prophylaxis (GroupA) 5CA
Assessment for VTE risk factors (GroupA) IN
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
1.4.0
A
VTE (GroupA)
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Pharmacological prophylaxis (GroupA) 5CA
Assessment for VTE risk factors (GroupA) IN
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/04/04
Released
1.3.0
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
Internal system migration related to merging adult and pediatric contexts.
2018/11/01
Released
1.2.2
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
Internal system migration related to score text replacement from E to N
2018/04/09
Released
1.2.1
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
2018/04/09
Released (Under revision)
1.2.0
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
2018/03/19
Released
1.2.0
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
2018/03/19
Released (Under revision)
1.1.0
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
2018/03/19
Released
1.1.0
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
2018/03/19
Released (Under revision)
1.0.1
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
2018/01/11
Released
1.0.1
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
2017/10/23
Released
1.0.0
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
¤ Powered by BCM's Genboree.